{
    "clinical_study": {
        "@rank": "135984", 
        "arm_group": [
            {
                "arm_group_label": "Part A, Cohort A: LY2605541", 
                "arm_group_type": "Experimental", 
                "description": "Healthy participants will receive LY2605541 (22 up to 66 nanomoles [nmol]) intravenously (IV) over 8 hours in 3 of 4 study periods.  Each dose is separated by a minimum 6 day washout period."
            }, 
            {
                "arm_group_label": "Part A, Cohort A; Insulin Glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "Healthy participants will receive insulin glargine (30 milliunits/meter squared/minute [mU/m^2/min]) IV over 8 hours in 1 of 4 study periods, separated by a minimum 6 day washout period."
            }, 
            {
                "arm_group_label": "Part A, Cohort B; LY2605541", 
                "arm_group_type": "Experimental", 
                "description": "Healthy participants will receive LY2605541 (22 up to 66 nmol) administered IV over 8 hours in 3 of 4 study periods.  Dose may be adjusted based on Cohort A results.  Each dose is separated by a minimum 6 day washout period."
            }, 
            {
                "arm_group_label": "Part A, Cohort B; Insulin Glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "Healthy participants will receive insulin glargine (60 mU/m^2/min) IV over 8 hours in 1 of 4 study periods.  Dose may be adjusted based on Cohort A results.  Each dose is separated by a minimum 6 day washout period."
            }, 
            {
                "arm_group_label": "Part B; LY2605541", 
                "arm_group_type": "Experimental", 
                "description": "Participants with T1DM will receive LY2605541 administered IV up to 10 hours in 2 of 4 study periods.  Dose determined by Part A results.  Each dose is separated by a minimum 6 day washout period."
            }, 
            {
                "arm_group_label": "Part B; Insulin Glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants with T1DM will receive insulin glargine administered IV over 8 hours in 2 of 4 study periods.  Dose determined by Part A results.    Each dose is separated by a minimum 6 day washout period."
            }
        ], 
        "brief_summary": {
            "textblock": "LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus.\n      This study is designed to understand how the body handles the investigational drug, what\n      effect this investigational drug has on the body and how much should be given. This study\n      will also measure how much of the investigational drug gets into the blood stream and how\n      long it takes the body to get rid of it. The study has 2 parts: Part A will be conducted in\n      healthy participants. Part B will be conducted in participants with type 1 diabetes mellitus\n      (T1DM). This study will take approximately 10-14 days spread over 6-20 weeks, not including\n      screening. Screening will be performed within 30 days of the start of the study."
        }, 
        "brief_title": "A Study of LY2605541 Versus Insulin Glargine on Blood Sugar", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Volunteers", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All Participants\n\n          -  Are healthy males or participants with T1DM\n\n          -  Have a screening body mass index (BMI) of 20.0-29.9 kilograms per square meter\n             (kg/m^2)\n\n        Healthy Participants ONLY\n\n          -  Are overtly healthy, as determined by medical history and physical examination\n\n          -  Have a fasting blood glucose <108 milligrams/deciliter (mg/dL) (6.0 millimoles/liter\n             [mmol/L]) at screening\n\n        Participants with T1DM ONLY\n\n          -  Have a diagnosis of T1DM for at least 1 year based on medical history\n\n          -  Have a screening c-peptide <0.5 nanogram/milliliter (ng/mL)\n\n          -  Have a hemoglobin A1c (HbA1c) of 6.0 to 9.0% at screening\n\n          -  Have had no episodes of severe hypoglycemia in the past 6 months (severe hypoglycemia\n             is defined as having neurological symptoms consistent with neuroglycopenia and having\n             required assistance in treatment by a second party)\n\n        Exclusion Criteria:\n\n        All Participants\n\n          -  Have a hemoglobin level <12.0 grams/deciliter (g/dL) at screening\n\n          -  Is currently a smoker or used tobacco products on a regular basis in the 6 months\n             prior to screening, or intending to smoke during the study\n\n        Healthy Participants ONLY\n\n        \u2022 Regular use or intended use of over-the counter or prescription medication within 7 and\n        14 days, respectively, prior to dosing (apart from vitamin/mineral supplements or\n        occasional use of acetaminophen or ibuprofen). If this situation arises, inclusion of an\n        otherwise suitable participants may be at the discretion of the investigator\n\n        Participants with T1DM ONLY\n\n          -  Regular use or intended use of any over-the-counter or prescription medications or\n             nutritional supplements that affect blood glucose or the body's sensitivity to\n             insulin or that promote weight loss within 14 days prior to dosing\n\n          -  Are receiving chronic (lasting longer than 14 consecutive days) systemic or inhaled\n             glucocorticoid therapy (excluding topical, intra-articular, and intraocular\n             preparations) or have received such therapy within the 4 weeks before dosing\n\n          -  Require a total daily insulin dose exceeding 100 units (U)\n\n          -  Have fasting triglycerides >400 mg/dL"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654380", 
            "org_study_id": "12157", 
            "secondary_id": "I2R-MC-BIAV"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Part A, Cohort A: LY2605541", 
                    "Part A, Cohort B; LY2605541", 
                    "Part B; LY2605541"
                ], 
                "description": "LY2605541 is a solution. The concentration of LY2605541 is 100 U/mL", 
                "intervention_name": "LY2605541", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A, Cohort A; Insulin Glargine", 
                    "Part A, Cohort B; Insulin Glargine", 
                    "Part B; Insulin Glargine"
                ], 
                "description": "Insulin glargine is a 100 U/mL solution in 10 mL glass vial", 
                "intervention_name": "Insulin glargine", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 18, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "Comparison of the Effects of LY2605541 and Insulin Glargine on Endogenous Glucose Output and Peripheral Glucose Disposal in Healthy Subjects and Patients With Type 1 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Part B: Glucodynamics: Endogenous glucose output", 
                "safety_issue": "No", 
                "time_frame": "Up to 8 hours, duration of the euglycemic glucose clamp"
            }, 
            {
                "measure": "Part B: Glycodynamics: Glucose disposal", 
                "safety_issue": "No", 
                "time_frame": "Up to 10 hours, duration of the euglycemic glucose clamp"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654380"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "collaborator": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}